Rabbit Recombinant Monoclonal CD130 (gp130) antibody. Carrier free. Suitable for WB, I-ELISA and reacts with Human, Recombinant full length protein - Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Constituents: PBS
WB | I-ELISA | |
---|---|---|
Human | Tested | Expected |
Recombinant full length protein - Human | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes We recommend that the customer optimizes the western blotting conditions. |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Signal-transducing molecule (PubMed:2261637). The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize IL6ST for initiating signal transmission. Binding of IL6 to IL6R induces IL6ST homodimerization and formation of a high-affinity receptor complex, which activates the intracellular JAK-MAPK and JAK-STAT3 signaling pathways (PubMed:19915009, PubMed:2261637, PubMed:23294003). That causes phosphorylation of IL6ST tyrosine residues which in turn activates STAT3 (PubMed:19915009, PubMed:23294003, PubMed:25731159). In parallel, the IL6 signaling pathway induces the expression of two cytokine receptor signaling inhibitors, SOCS1 and SOCS3, which inhibit JAK and terminate the activity of the IL6 signaling pathway as a negative feedback loop (By similarity). Also activates the yes-associated protein 1 (YAP) and NOTCH pathways to control inflammation-induced epithelial regeneration, independently of STAT3 (By similarity). Acts as a receptor for the neuroprotective peptide humanin as part of a complex with IL27RA/WSX1 and CNTFR (PubMed:19386761). Mediates signals which regulate immune response, hematopoiesis, pain control and bone metabolism (By similarity). Has a role in embryonic development (By similarity). Essential for survival of motor and sensory neurons and for differentiation of astrocytes (By similarity). Required for expression of TRPA1 in nociceptive neurons (By similarity). Required for the maintenance of PTH1R expression in the osteoblast lineage and for the stimulation of PTH-induced osteoblast differentiation (By similarity). Required for normal trabecular bone mass and cortical bone composition (By similarity). Isoform 2. Binds to the soluble IL6:sIL6R complex (hyper-IL6), thereby blocking IL6 trans-signaling. Inhibits sIL6R-dependent acute phase response (PubMed:11121117, PubMed:21990364, PubMed:30279168). Also blocks IL11 cluster signaling through IL11R (PubMed:30279168).
CD130, Interleukin-6 receptor subunit beta, IL-6 receptor subunit beta, IL-6R subunit beta, IL-6R-beta, IL-6RB, CDw130, Interleukin-6 signal transducer, Membrane glycoprotein 130, Oncostatin-M receptor subunit alpha, gp130, IL6ST
Rabbit Recombinant Monoclonal CD130 (gp130) antibody. Carrier free. Suitable for WB, I-ELISA and reacts with Human, Recombinant full length protein - Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Constituents: PBS
ab234105 is the carrier-free version of Anti-CD130 (gp130) antibody [EPR21732] ab217671.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
CD130 also known as gp130 or the IL-6 signal transducer (IL6ST) is a protein weighing around 130 kDa. This receptor is encoded by the IL6ST gene and widely expressed on the surface of cells across multiple tissues. CD130 functions mechanically as a signal transducing receptor facilitating the assembly of receptor complexes necessary for the initiation of signal transduction. It plays a major role in cytokine receptor signaling particularly interacting with interleukin-6 (IL-6) family cytokines.
CD130 functions as part of the high-affinity receptor complex for certain cytokines. It partners with other receptors such as CD126 to form a complex that initiates signaling pathways after ligand binding contributing to a range of immune responses. Its role is thorough across many cellular processes including differentiation proliferation and apoptosis. In addition to immune signaling CD130 is involved in several growth factor signaling pathways.
CD130 serves a significant role in signal transduction particularly in the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. It works in concert with related proteins like JAK1 and STAT3 to transmit signals from extracellular cytokines to the nucleus influencing gene expression. Additionally CD130 can also be found active in the MAPK/ERK pathway which is important for cellular response to growth signals.
CD130 plays a connection especially to inflammatory conditions and certain cancers. Aberrant signaling involving CD130 has been linked to disorders like rheumatoid arthritis where it contributes to the inflammation process. Additionally it relates to multiple myeloma a cancer where abnormal CD130 interactions with proteins like IL-6 may enhance cell survival and proliferation presenting potential targets for therapeutic intervention.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using the same antibody clone in a different buffer formulation (Anti-CD130 (gp130) antibody [EPR21732] ab217671).
Lanes 1- 2: Merged signal (red and green). Green - Anti-CD130 (gp130) antibody [EPR21732] ab217671 observed at 130 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) observed at 37 kDa.
Anti-CD130 (gp130) antibody [EPR21732] ab217671 was shown to react with CD130 (gp130) in wild-type A549 cells in western blot. Loss of signal was observed when knockout cell line ab266939 (knockout cell lysate ab257208) was used. Wild-type A549 and IL6ST knockout A549 cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-CD130 (gp130) antibody [EPR21732] ab217671 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-CD130 (gp130) antibody [EPR21732] (Anti-CD130 (gp130) antibody [EPR21732] ab217671) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: IL6ST knockout A549 cell lysate at 20 µg
Lane 3: PC3 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 104 kDa
Observed band size: 130 kDa
This data was developed using the same antibody clone in a different buffer formulation (Anti-CD130 (gp130) antibody [EPR21732] ab217671).
Lanes 1 - 2: Merged signal (red and green). Green - Anti-CD130 (gp130) antibody [EPR21732] ab217671 observed at 130 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-CD130 (gp130) antibody [EPR21732] ab217671 Anti-CD130 (gp130) antibody [EPR21732] was shown to specifically react with CD130 (gp130) in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human IL6ST (CD130/gp130) knockout HeLa cell line ab265767 (knockout cell lysate Human IL6ST (CD130/gp130) knockout HeLa cell lysate ab257205) was used. Wild-type and CD130 (gp130) knockout samples were subjected to SDS-PAGE. Anti-CD130 (gp130) antibody [EPR21732] ab217671 and Anti-GAPDH antibody [6C5] - Loading Control were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-CD130 (gp130) antibody [EPR21732] (Anti-CD130 (gp130) antibody [EPR21732] ab217671) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: IL6ST knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human IL6ST (CD130/gp130) knockout HeLa cell line (Human IL6ST (CD130/gp130) knockout HeLa cell line ab265767)
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 104 kDa
Observed band size: 130 kDa
This data was developed using Anti-CD130 (gp130) antibody [EPR21732] ab217671, the same antibody clone in a different buffer formulation.ELISA analysis of IL6ST recombinant protein at 1000 ng/mL with Anti-CD130 (gp130) antibody [EPR21732] ab217671. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.
This data was developed using the same antibody clone in a different buffer formulation (Anti-CD130 (gp130) antibody [EPR21732] ab217671).
Lanes 1-2: Merged signal (red and green). Green - Anti-CD130 (gp130) antibody [EPR21732] ab217671 observed at 130 kDa. Red - loading control Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 observed at 50 kDa.
Anti-CD130 (gp130) antibody [EPR21732] ab217671 Anti-CD130 (gp130) antibody [EPR21732] was shown to specifically react with CD130 (gp130) in wild-type A549 cells. Loss of signal was observed when knockout cell line Human IL6ST (CD130/gp130) knockout A549 cell line ab266938 (knockout cell lysate Human IL6ST (CD130/gp130) knockout A549 cell lysate ab257207) was used. Wild-type and CD130 (gp130) knockout samples were subjected to SDS-PAGE. Anti-CD130 (gp130) antibody [EPR21732] ab217671 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-CD130 (gp130) antibody [EPR21732] (Anti-CD130 (gp130) antibody [EPR21732] ab217671) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: IL6ST knockout A549 cell lysate at 20 µg
Lane 2: Western blot - Human IL6ST (CD130/gp130) knockout A549 cell line (Human IL6ST (CD130/gp130) knockout A549 cell line ab266938)
Performed under reducing conditions.
Predicted band size: 104 kDa
Observed band size: 130 kDa
Anti-CD130 (gp130) antibody [EPR21732] ab217671 was shown to specifically react with CD130 (gp130) in wild-type HAP1 cells as the signal was lost in CD130 (gp130) knockout cells. Wild-type and CD130 (gp130) knockout samples were subjected to SDS-PAGE. Anti-CD130 (gp130) antibody [EPR21732] ab217671 and Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 (Human anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/200000 dilution respectively. Blots were developed with Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/100,000 dilution for 1 hour at room temperature before imaging. The blot was developed on a BIO-RAD® ChemiDoc™ MP instrument using the ECL technique.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-CD130 (gp130) antibody [EPR21732] ab217671).
All lanes: Western blot - Anti-CD130 (gp130) antibody [EPR21732] (Anti-CD130 (gp130) antibody [EPR21732] ab217671) at 1/1000 dilution
Lane 1: Wild-type HAP1 (human chronic myelogenous leukemia cell line) whole cell lysate at 20 µg
Lane 2: CD130 (gp130) knockout HAP1 whole cell lysate at 20 µg
Lane 3: PC-3 (human prostate adenocarcinoma cell line) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 104 kDa
Observed band size: 130 kDa
Exposure time: 114s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com